Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to competitors Pfizer and Merck's vaccines and stronger responses against some strains. This success highlights a major opportunity in the adult pneumococcal vaccine market, potentially worth $3-6 billion. Vaxcyte shares surged 57% after the announcement, signaling strong investor confidence.
Vaxcyte's recent Phase 3 trial success comes as 61 out of 100 health-sector US stocks tradable on Pluang rose today. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: Cytokinetics Inc (CYTK) fell 4.59% to USD 62.59 with a typical hold time of 19 days, 10X Genomics Inc (TXG) rose 4.53% to USD 97.74 with 73% buy order activity and a typical hold time of 93 days, and Danaher Corporation (DHR) dropped 4.47% to USD 211.68 with 72% buy order activity and a typical hold time of 69 days.
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...
BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...
Nelnet Business Services (NBS) has acquired Entab Infotech, a leading Indian provider of school administration and learning technology software. This acquisition supports NBS's international growth strategy by entering India’s large K-12 education ma...
Franco-Nevada Corporation acquired 10 million common shares of Kenorland Minerals, representing 12.42% of the company, for $22.2 million through private agreements. This marks Franco-Nevada's first investment in Kenorland, a mineral exploration compa...
